Alzheimer Disease in 2020
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Remarkable advances in unraveling the biological underpinnings of Alzheimer disease (AD) have occurred during the last 25 years. Despite this, we have made only the smallest of dents in the development of truly disease-modifying treatments. What will change over the next 10 years? While the answer is not clear, we make several predictions on the state of the field in 2020, based on the rich knowledge described in the other contributions in this collection. As such, our predictions represent some of the principal unresolved questions that we believe deserve special investigative attention in the coming decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets
Lee, V. M.-Y., Brunden, K. R., Hutton, M., & Trojanowski, J. Q. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006437 · Cited by 122 · cited 2×
“A much hoped-for outcome of the intensive therapeutic research reviewed by Schenk et al. (2011), Lee et al. (2011), and Aisen et al. (2011) is that at least one of the agents currently in phase 2 or 3 clinical trials will have shown sufficient efficacy and safety to have been approved as the first…”
Background
Cited by
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Self-citationTau promotes neurodegeneration through global chromatin relaxation
Frost, B., Hemberg, M., Lewis, J., & Feany, M. B. (2014) · Nature Neuroscience · doi:10.1038/nn.3639 · Cited by 495
“Flies were collected in fresh vials on the day of eclosion and were transferred without anesthesia to fresh vials on days 3, 5, 7, and 9.”
Eimer, W. A., & Vassar, R. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-2 · Cited by 425
Synaptopathies: synaptic dysfunction in neurological disorders – A review from students to students
Lepeta, K., Lourenco, M. V., Schweitzer, B. C., Martino Adami, P. V., Banerjee, P., Catuara‐Solarz, S., de La Fuente Revenga, M., Guillem, A. M., Haidar, M., Ijomone, O. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13713 · Cited by 386
Zhang, X., Tian, Y., Li, Z., Tian, X., Sun, H., Liu, H., Moore, A., & Ran, C. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405239v · Cited by 354
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)
Singh, N. A., Mandal, A. K. A., & Khan, Z. A. (2015) · Nutrition Journal · doi:10.1186/s12937-016-0179-4 · Cited by 314
A Human Stem Cell Model of Early Alzheimer’s Disease Pathology in Down Syndrome
Shi, Y., Kirwan, P., Smith, J., MacLean, G., Orkin, S. H., & Livesey, F. J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003771 · Cited by 310
Immunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284
Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins
Ciryam, P., Tartaglia, G. G., Morimoto, R. I., Dobson, C. M., & Vendruscolo, M. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.043 · Cited by 270
Degradation of tau protein by autophagy and proteasomal pathways
Wang, Y., & Mandelkow, E. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120071 · Cited by 166
Self-citationKetones block amyloid entry and improve cognition in an Alzheimer's model
Yin, J. X., Maalouf, M., Han, P., Zhao, M., Gao, M., Dharshaun, T., Ryan, C., Whitelegge, J., Wu, J., Eisenberg, D., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.11.018 · Cited by 151
“clinical treatments has been achieved (Holtzman et al., 2012).”
Impaired Autophagy in APOE4 Astrocytes
Simonovitch, S., Schmukler, E., Bespalko, A., Iram, T., Frenkel, D., Holtzman, D. M., Masliah, E., Michaelson, D. M., & Pinkas-Kramarski, R. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-151101 · Cited by 136
“For example, ApoE receptors such as LRP and ApoER2, which play important roles in key cellular processes [45, 46], were shown to be affected differentially by ApoE4 and ApoE3 [47, 48].”
Self-citationSorting receptor SORLA – a trafficking path to avoid Alzheimer disease
Willnow, T. E., & Andersen, O. M. (2013) · Journal of Cell Science · doi:10.1242/jcs.125393 · Cited by 121
Spuch, C., Ortolano, S., & Navarro, C. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00269 · Cited by 107
Alfonso, S. I., Callender, J. A., Hooli, B., Antal, C. E., Mullin, K., Sherman, M. A., Lesné, S. E., Leitges, M., Newton, A. C., Tanzi, R. E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf6209 · Cited by 103
“Familial forms of AD (hereditary early-onset AD), which account for less than 10% of AD cases, are caused by mutations in genes encoding amyloid precursor protein (APP) or b- and g-secretases (enzymes that cleave APP) that result in increased abundance of the most toxic form of Ab (9).”
BackgroundInfluentialLipid metabolism in Alzheimer’s disease
Liu, Q., & Zhang, J. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1410-3 · Cited by 101
“Mutations in the genes for Presenilin 1, Presenilin 2, and APP can cause early-onset, autosomal dominant familial AD, but these cases only account for <1% of the total AD cases([68]).”
BackgroundAbdAlla, S., Langer, A., Fu, X., & Quitterer, U. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140816917 · Cited by 100
Jianming, W., & Ling, L. (2016) · The Journal of Biomedical Research · doi:10.7555/jbr.30.20150131 · Cited by 87
Walter, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.704981 · Cited by 80
Wang, Q., Wang, Y., Liu, J., Sutphen, C. L., Cruchaga, C., Blazey, T., Gordon, B. A., Su, Y., Chen, C., Shimony, J. S., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101767 · Cited by 63
Liu, S., Breitbart, A., Sun, Y., Mehta, P. D., Boutajangout, A., Scholtzova, H., & Wisniewski, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12484 · Cited by 60
Sorting receptor sortilin—a culprit in cardiovascular and neurological diseases
Carlo, A.-S., Nykjaer, A., & Willnow, T. E. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1152-3 · Cited by 56
Dafnis, I., Argyri, L., Sagnou, M., Tzinia, A., Tsilibary, E. C., Stratikos, E., & Chroni, A. (2016) · Scientific Reports · doi:10.1038/srep30654 · Cited by 38
Extracellular Proteolysis of Apolipoprotein E (apoE) by Secreted Serine Neuronal Protease
Tamboli, I. Y., Heo, D., & Rebeck, G. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093120 · Cited by 35
Role of Cofilin in Alzheimer’s Disease
Wang, Q., Yuan, W., Yang, X., Wang, Y., Li, Y., & Qiao, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.584898 · Cited by 35
Axonal Terminals Exposed to Amyloid-β May Not Lead to Pre-Synaptic Axonal Damage
Sun, S.-W., Nishioka, C., Labib, W., & Liang, H.-F. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-142154 · Cited by 8
Metadata
- Authors
- Holtzman, D. M., Mandelkow, E., & Selkoe, D. J.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-11-01
- Volume
- 2
- Issue
- 11
- Pages
- a011585-a011585
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2167645268
- Cited by
- 151
- References
- 1
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.